bluebird bio, Inc. (NASDAQ:BLUE) has been the object of insider selling activity recently. Jeffrey T. Walsh, Chief Financial reported the sale of 2,500 shares. The shares were purchased at an average price of $100.19. The Chief Financial now owns $2,735,688 of the stock according to the SEC filing. Chief Scientific Officer Philip D. Gregory sold 2,250 shares at an average price of $103.83 on July 6th. That brings Gregory’s holdings to $3,268,984 per an SEC filing yesterday.
Daniel Lynch, Director sold $275,500 worth of shares at an average price of $110.20 on Thu the 8th. The Director now owns $308,560 of the stock as recorded in a recent Form 4 SEC filing.
bluebird bio, Inc., launched on April 16, 1992, is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Business’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia (TDT) and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology are built upon its lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline..
Here are some other firms who have updated their holdings. Creative Planning downsized its ownership by selling 47,231 shares a decrease of 98.5% from 03/31/2017 to 06/30/2017. Creative Planning owns 714 shares with a value of $75,000. The total value of its holdings decreased 98.3%. Bank Of Montreal /can/ cut its position by shedding 89 shares a decrease of 11.6%. Bank Of Montreal /can/ now controls 677 shares worth $71,000. The value of the position overall is up by 1.4%.
Fny Partners Fund Lp augmented its holdings by buying 25,595 shares an increase of 511,900.0% as of 03/31/2017. Fny Partners Fund Lp controls 25,600 shares valued at $2,327,000. The value of the position overall is up by 0.0%. Morgan Stanley added to its investment by buying 718 shares an increase of 140.0% in the quarter. Morgan Stanley currently owns 1,231 shares valued at $112,000. The value of the position overall is up by 250.0%.
July 11 investment analysts at Morgan Stanley left the stock rating at “Equal-Weight” but moved up the price target from $69.00 to $103.00. On June 30 the company was changed to a “Neutral” according to a BTIG Research report which was a cut from the previous “Buy” rating.
On June 16 the company was downgraded to “Reduce” from “Buy” in a report issued by Standpoint Research. BMO Capital upgraded the stock and raised the price target on June 6 changing the price objective from $61.00 to $108.00 and changing the rating from “Market Perform” to “Outperform”.
On June 6 the stock rating was upgraded from “Market Perform” to “Outperform” with a current price target of $108.00 by analysts at BMO Capital. On May 30, 2017 Standpoint Research added BLUE to its research portfolio by announcing an initial rating of “Buy”.
The company is up by 0.90% since yesterday’s close of $94.85. It is trading at $95.70 which is marginally lower than $97.43, the stock’s 50 day moving average and which is slightly above the 200 day moving average of $83.86. The 50 day moving average was down $-1.73 or -1.78% and the 200 day average moved up $11.84.
As of the latest earnings report the EPS was $-7.21 and is estimated to be $-6.72 for the current year with 40,950,000 shares presently outstanding. Next quarter’s EPS is expected be $-1.68 with next year’s EPS anticipated to be $-6.83.
Investors are more bearish on shares of bluebird bio, Inc. as indicated by the uptick in short interest. The stock saw a rise in short interest of 2.25% between June 15, 2017 and May 31, 2017. Short interest increased 176,027 over that timeframe. With short interest at 7,987,331 and short average daily volume at 1,672,198, days to cover is 4.8 and the short interest percentage is 0.20% as of May 31.